Treatment of rheumatoid arthritis. Evolution of concepts and strategies;Le traitement de la polyarthrite rhumatoide. Evolution des idees et des strategies

Revue de Medecine Interne

Volumn 20, Issue 2, 1999, Pages 171-178

  Dubost, J J ^a   Soubrier, M ^a   Sauvezie, B ^a  

^a Unité d'Immunologie Clinique   (France)

Author keywords

Rheumatoid arthritis; Second line drugs disease; Steroids; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; BONE INJURY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT PLANNING;

EID: 0032719327     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)83037-9     Document Type: Article

References (57)

1. Medsger TA Jr, Masi AT. Epidemiology of the rheumatic diseases. McCarty DJ. Arthritis and Allied Conditions. 1985;9-39 Lea & Febiger, Philadelphia.
2. Harris ED Jr. Rheumatoid arthritis: the clinical syndrome. Kelley WN, Harris ED Jr, Ruddy S, Sledge CB. Textbook of Rheumatology. 1985;915-950 WB Saunders, Philadelphia.
3. O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis. Follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med. 76:1972;573-577.
4. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol. 12:1985;245-252.
5. Wolfe F. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol. 17:1990;24-32. Suppl 22.
6. Symmons D. Excess mortality in rheumatoid arthritis - Is it the disease or the drugs? J Rheumatol. 22:1995;2200-2201.
7. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - Lessons from Hodgkin's disease and coronary artery disease. J Rheumatol. 17:1990;1582-1585.
8. Van Leeuwen MA, Van Rijswijk MH, Sluiter WJ, Van Riel PLCM, Kuper IH, Van de Putte LBA, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol. 24:1997;20-27.
9. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 16:1989;585-591.
10. Forslind K, Larsson EM, Johansson A, Svensson B. Detection of joint pathology by magnetic resonance imaging in patients with early rheumatoid arthritis. Br J Rheumatol. 36:1997;683-688.
11. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol. 18:1991;1290-1297.
12. Egsmose C, Lund NB, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol. 22:1995;2208-2213.
13. Van der Heide A, Jacobs JWG, Bijlsma JWS, Heurkens AHM, Van Booma-Frankfort C, Van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 124:1996;699-707.
14. Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "Sawtooth" strategy. Arthritis Rheum. 39:1996;996-1005.
15. Combe B. Stratégie des traitements de fond de la polyarthrite rhumatoïde. Rev Rhum. 64:1997;183SP-191SP.
16. Pincus T, Callahan LF. How many types of patients meet classification criteria of rheumatoid arthritis? J Rheumatol. 21:1994;1385-1388.
17. Emery P. Prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol. 24:1997;1436-1442.
18. Combe B. Les facteurs de pronostic des rhumatismes inflammatoires au début de la maladie. Rev Méd Interne. 17:1996;224-230.
19. Wordsworth P, Pile KD, Buckely JD, Lanchbury JSS, Ollie RB, Lathrop M, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet. 51:1992;585-591.
20. Weyand CM, McCarty TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest. 95:1995;2120-2126.
21. Benazet JF, Reviron D, Mercier P, Roux H, Roudier J. HLA-DRB1 alleles associated with rheumatoid arthritis in Southern France. Absence of extraarticular disease despite expression of the shared epitope. J Rheumatol. 22:1995;607-610.
22. Combe B, Eliaou JF, Daures JP, Meyeil O, Clot J, Sany J, et al. Prognostic factors in rheumatoid arthritis. Comparative study of 2 subsets of patients according to severity of articular damage. Br J Rheumatol. 34:1995;529-534.
23. Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum. 37:1994;1166-1170.
24. Wagner U, Kaltenhäuser S, Sauer H, Arnold S, Seidel W, Häntzschel H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum. 40:1997;341-351.
25. Suarez-Almazor ME, Tao S, Moustarah F, Russell AS, Maksymowych W. HLA-DR1, DR4 and DRB1 disease related subtypes in rheumatoid arthritis. Association with susceptibility but not severity in a city wide community based study. J Rheumatol. 22:1995;2027-2033.
26. Eberbardt K, Fex E, Johnson U, Wollheim FA. Association of HLA-DRB and-DQB genes with two and five year outcome in rheumatoid arthritis. Ann Rheum Dis. 55:1996;34-39.
27. Gotzsche P, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Br Med J. 316:1998;811-818.
28. Saag KG, Criswell LA, Sens KM, Nettlemnan MN, Kolluri S. Low dose corticosteroids in rheumatoid arthritis. A metaanalyse of their moderate term effectiveness. Arthritis Rheum. 39:1996;1818-1825.
29. Dennison EM. Corticosteroids in rheumatoid arthitis. Effective anti-inflammatory agents but doubts safety remain. Br Med J. 316:1998;789-790.
30. Kirwan J. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med. 333:1995;142-146.
31. Fries JF, Miller SR, Spitz PW, Williars CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 96:1989;645-655.
32. Myllykangas-Luosujärvi R, Aho K, Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1,666 patients with rheumatoid arthritis who have died. J Rheumatol. 22:1995;2214-2217.
33. Bannwarth B, Amor B. Iso-enzymes de la cyclo-oxygénase : COX-2, une cible nouvelle pour des anti-inflammatoires non stéroïdiens novateurs ? Rev Rhum. 63:1996;7S-9S.
34. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "Sawtooth" strategy. J Rheumatol. 17:1990;12-15. Suppl 22.
35. Cantagrel A. Traitement de la polyarthrite rhumatoïde : la corticothérapie par voie générale. Rev Rhum. 64:1997;129SP-136SP.
36. Felson DT, Anderson JJ, Meenan RF. The efficacity and toxicity of combination therapy in rheumatoid arthritis. Arthritis Rheum. 37:1994;1487-1491.
37. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 35:1992;259-269.
38. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate and the combination of the two in the treatment of rheumatoid arthritis. Arthritis Rheum. 38:1995;1799-1806.
39. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulphasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 334:1996;1287-1291.
40. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine A and methotrexate in severe rheumatoid arthritis. N Engl J Med. 333:1995;137-141.
41. Boers M, Verhoeven AC, Merkusse HM, Van de Laar MAFJ, Westhovens R, Van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 350:1997;309-318.
42. Dougados M, Cantagrel A, Goupille P, Schattenkirchner M, Meusser S, Paimela L, et al. Sulphasalazine (SASP), methotrexate (MTX) and the combination (COMBI) in early rheumatoid arthritis (RA): a double blind randomized study. [Abstract 462] Arthritis Rheum. 39:1996;1035. (Suppl).
43. Haagsma CJ, Van Riel PL, de Jong AJ, Van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized controlled double-blind, 52 week clinical trial. Br J Rheumatol. 36:1997;1082-1088.
44. Möttönen T, Hannonen P, Korpela M. Superiority of DMARD combination to single drug treatment strategy in early rheumatoid arthritis: remissions. [Abstract 1128] Arthritis Rheum. 40:1997;2195. (Suppl).
45. Scott DL, Dawes PT, Tunn E, Fowler PD, Shadforth MF, Fisher J, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis. A proposition, randomized, placebo controlled study. Br J Rheumatol. 28:1989;128-133.
46. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis. No benefite of addition of hydroxychloroquine to patients with suboptimal response to IM gold therapy. J Rheumatol. 20:1993;645-649.
47. Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis. 52:1993;711-715.
48. Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM. Controlled trial of hydoxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum. 27:1984;267-276.
49. Ferraz MB, Pinheiro GRC, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. Scand J Rheumatol. 23:1994;231-236.
50. Fries JF, Singh G, Lenert L, Furst DE. Aspirin hydroxychloroquine and hepatic enzyme abnormalitis with methotrexate in rheumatoid arthritis. Arthritis Rheum. 33:1990;1611-1619.
51. Kantor TG. Order out of chaos - The primary mission of the pyramid. J Rheumatol. 17:1990;1580-1581.
52. Mc Duffie FC. How we got to be where we are. J Rheumatol. 17:1990;1-3. Suppl 25.
53. Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered? Mayo Clin Proc. 63:1988;58-68.
54. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. i:1987;1108-1111.
55. Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 309:1983;1023-1028.
56. Wilske KR, Healey LA. Remodeling the pyramid - A concept whose time has come. J Rheumatol. 16:1989;565-567.
57. Hess EV, Luggen ME. Remodeling the pyramid - A concept whose time has not yet come. J Rheumatol. 16:1989;1175-1176.